Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at NIH, Predicine, Mainz Biomed, Bio-Techne, More

National Institutes of Health: Holly Garriock

Holly Garriock has been appointed as chief cohort development officer of the National Institutes of Health's All of Us research program. Since 2016, she has held several roles at All of Us, including deputy director for the division of scientific programs and program officer for the effort's healthcare provider organizations. Before that, she was a program officer at the National Institute of Mental Health. Garriock holds an undergraduate degree from Bishop's University in Canada and a PhD in genetics from the University of Arizona.

Predicine: Linh Le

Linh Le has been appointed as CFO of Predicine. He comes to the molecular diagnostics company from Ambry Genetics, where he was chief operating officer. Previously, he spent more than 14 years overseeing financial operations and global expansion at Medtronic's Diabetes Group.

Mainz Biomed: Karen Richards

Mainz Biomed has appointed Karen Richards as VP of regulatory affairs. She will also serve as SVP of in vitro diagnostics and quality at Precision for Medicine. According to Mainz Biomed, Richards was responsible for the approval of laboratory tests in all 50 states in the US requiring a license and has implemented quality systems for diagnostic products to meet various regulatory and certification requirements, including those of the US Food and Drug Administration, CLIA, and the College of American Pathologists.

Bio-Techne: William Geist, David Eansor

Bio-Techne has appointed William Geist as president of its protein sciences segment, effective Jan. 3, 2022. Geist was most recently chief operating officer at Quanterix, where he was responsible for enterprise-wide operations and strategy deployment. Previously, he was VP and general manager for Thermo Fisher Scientific's protein and cell analysis and qPCR business units, and VP of Qiagen's QuantaBiosciences.

Geist succeeds David Eansor, who is retiring and will remain with Bio-Techne through the end of February 2022 to ensure a smooth transition.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.